Ozanimod Hydrochloride Patent Expiration
Ozanimod Hydrochloride is Used for treating ulcerative colitis and multiple sclerosis in adults. It was first introduced by Bristol Myers Squibb Co
Ozanimod Hydrochloride Patents
Given below is the list of patents protecting Ozanimod Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zeposia | US11680050 | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof | Sep 30, 2038 | Bristol |
| Zeposia | US10239846 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | Nov 15, 2030 | Bristol |
| Zeposia | US8481573 | Modulators of sphingosine phosphate receptors | May 14, 2029 | Bristol |
| Zeposia | US8796318 | Modulators of sphingosine phosphate receptors | May 14, 2029 | Bristol |
| Zeposia | US9382217 | Modulators of sphingosine phosphate receptors | May 14, 2029 | Bristol |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ozanimod Hydrochloride's patents.
Latest Legal Activities on Ozanimod Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Ozanimod Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Dec, 2023 | US9382217 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8481573 |
| transaction for FDA Determination of Regulatory Review Period | 28 Nov, 2023 | US8481573 |
| Recordation of Patent eGrant | 20 Jun, 2023 | US11680050 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Jun, 2023 | US11680050 |
| Recordation of Patent Grant Mailed Critical | 20 Jun, 2023 | US11680050 |
| Email Notification Critical | 20 Jun, 2023 | US11680050 |
| Mail Patent eGrant Notification | 20 Jun, 2023 | US11680050 |
| Electronic Review Critical | 20 Jun, 2023 | US11680050 |
| Patent eGrant Notification | 20 Jun, 2023 | US11680050 |
Ozanimod Hydrochloride's Family Patents
